mcq-2557-psu

7/24/2019 MCQ-2557-PSU

1/28

Final version | Maximum2017 Rx30 | Prince of Songkla Universit

!isclaimer " !"!#$#%$#!&&'(&

!!" ''(&!!" !( 1/2557 ( ")&! * ""!+,(-*(-* ( 120 "')!- 3 &(." (( )%!!(-** " / *)"(

! 5 (-* ( c#oice ! $$$%%&,))",+#

" 1 (-* !*""+#-555++ 01%"** -( ,+"21%

)!(-*))+# !*(-*))$ -!!%+# !*!!(-*(%$ 0"/-!,"!#+#!*$2

!" (!&"!+& )!(% 1% ,)!''(&!!"

!!, &! )!*"( !,.3"!+&)!"()"!!% -(- ) )-,.3# ,)!#% "( Everything under the sun "!"

"! +!"- !"-"*,- 444444

' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '

""#$%&'#"&))'*)"" **)"" "%'1(2$$7' "+') !*,+ 2$$7 - 0*+00 , 12+00 . ")' M-. 11

/"0+'1$#& 10 "!!""! *

1*!(5!,!-!61 !1(!( $#"!(-" penicillins

1+ "1-%'2&'!2"# "'%

(1)

)&7((2)

!,"("(3)

-,(4) -,-((,(5)

-,Note -( !"#1/2554

2+ !3"'""!02""4#-3532 %"-(1)

!"((2)

1#-"&((3) -!(4)

+(-3!(5)

!

3+ !% # "-"3'%(1)

$u%%ing &lcohol

(2)

"hlorhe'idine

(3)

rrig&ted nor&l s&line solution

(4)

cetic &cid

(5)

ovidone iodine

MCQ 11 : 1/2557

7/24/2019 MCQ-2557-PSU

2/28

M-. 11 | 1(2$$7 | Page 2


/+ 2-- # "3"6)%''(1)

,ilver sul-&di&.ine cre&

(2)

'ytetr&cycline ointent

(3)

"hlor&phenicol gel

(4)

&citr&cin cre&(5)

Neoycin poder

$+ # '!2 $% "0 #- )%2!'3'!(1)

Streptococcus pyogenes

(2) Streptococcus pneumoniae

(3) Staphylococcus aureus

(4)

Staphylococcus epidemidis

(5)

Escherichia coli

+ # "3"7)'&)""& (1)

o'ycycline

(2)

"hlor&phenicol

(3)

,ul-&cillin

(4)

iclo'&cillin

(5) "lind&ycin

7+ *2-'"2#-# 3&)% MRS ositive "-)7)'&))8&'(1)

&citr&cin

(2)

olyy'in

(3)

Neoycin

(4)

!upirocin

(5)

"hlor&phenicol

)+ 9 " " 2 ! 2 Fanconisnrome

(1)

(2)

(3)

(4)

(5)

/"0+'2$# & 5 " .!! , (

.! -"(.-# ((!((!et-orin (500) 1'3 pc

,iv&st&tin (20) 1'1 pc

En&l&pril (10) 1'1 pc

!!!( 132/2 g6 ,128 g/d96 %

1" : 7;8/9) ? 7;5 (3;5 @ 5 E>/9)"

3

@1 (24 @ 32 E>/9) "& ;2 (; @ 10;5 g/d9)

7;1 (2;5 @ 4;8 g/d9) l% 2;1 (3;5 @ 5;5 g/d9)FN 32 (7 @ 20 g/d9) "r 2;5 (0; @ 1;2 g/d9)

!1(!("" $#"'$#

/+# "'%'*&9"3"%""&& Cstage&(1)

,t&ge

(2)

,t&ge

(3)

,t&ge

(4)

,t&ge C

(5)

,t&ge C

$+# '"& otassium- +$"0soium olstrene sulfonate 9 " / # -"3 -*(1)

!ucillin

(2)

syliu seed

(3)

9&ctulose

(4) ,or%it&l

(5)

!&gnesiu hydro'ide

+# 9"3"% "''* &- Canemia& &-40&-3"(1)

ypochroic icrocytic red cell

(2)

ypochroic norocytic red cell

(3)

yperchroic &crocytic red cell

(4)

yperchroic norocytic red cell

(5)

Norochroic norocytic red cell

7+3 # ""&Ferrous sulfate CFeS/&

(1)

,)!- ,(2) ,)$#"%(3)

!--!!(!!"("(4)

!!(!-(!"!+"!#1%"(5)

!!(!! ,)"!-*

)+2!#-

7/24/2019 MCQ-2557-PSU

11/28

M-. 11 | 1(2$$7 | Page 11


71+""&2+2"0 -#lorie #luminium#roxie ",'"&2+ USP3/ Chloride Dissolve 1. g in ! m" o# 2 $ nitric

acid% heat to boiling% add &ater to ma'e 1 m"% and

#ilter( a ).*m" portion o# the #iltrate% diluted &ith an

e+ual volume o# &ater% sho&s no more chloride than

corresponds to ., m" o# .2 $ hydrochloric acid

2#-""&2+"0 -#lorie 0+)$H "3"luminium #roxie 4atc# "#-'%(1)

$eGect *,!"6 "hloride #

" 0;70'# D#alassemia#1$

eriphera 'ood smear

#2$

4one marro 'iopsy

#3$

,(-*"444

75*/27"'% )'1 3" 2"2& D#allassemia --' & '3 2$

0

#2$

25

#3$

50

#)$

75

#5$

100

7)*# 1" 2- !esferrioxamine 0mg(kg(a +"2" !esferrioxamine 2$0 mg(m; ,' :E infusion "&&-10 ) 3 0 ri. rate ( " ''

3"- 2 g(vial$

50 mg/hr

#2$

100 mg/hr

#3$

150 mg/hr

#)$

200 mg/hr

#5$

250 mg/hr

50*">' !esferrioxamine '"'$%'%1'"!!0*#1$

p:

#2$

teriity

#3$

yrogen

#)$

articuate matter

#5$ smoarity o( soution

51*3"" !esferrioxamine ')"1,!2-

A B C

D E

#1$

!

#2$ 4

#3$

C

#)$

#5$

E

52*2-1" !esferrioxamine # &-'')$1/4$ *)" "'%1"#1$

% ( es(errio"amine 1% (

(#2$

% !!&1!

es(errio"amine-9-1% ((

#3$

!!(! !3(#)$

444 ,(-*"444

/"0+'12& 10 .((!:(-

$--$- "-* "!(!/(15("!)!("!(!/(1"

53*"8-%1/#1$

--,"$- , -##2$

$-A&* & povidone iodine

#3$

&$- ru''ing acoho

#)$

-*.)&$$- - $-#5$

!$#+#(3(3*!(5$- -/

(1(5(

7/24/2019 MCQ-2557-PSU

27/28

M,- 12 | 1(2$$7 | Page 27


5*/#1$

$#",!( immunogo'uin

#2$

$#,!( immunogo'uin ( -

/1,!()( 7

#3$

$#,!( immunogo'uin /(!.(!(#)$

$#",!((1#5$

$#,!((1.!/)$(#intraderma$ )( 0? 3? 7? 1) - 30

5$*2'%1"">'4'- 3 $ &>'1"#1$

"/(1""#2$

/(1" 1 ")(.( #( 0$

#3$

/(1" 2 ")( 0 - 3

#)$

/(1" 3 ")( 0? 3 - 7

#5$

!"/(1)"("

5*"0''+24' 5!"'%11'2 3)11 &'&1"#1$

!"/(1" 1 )"

#2$

/" 2 ( "+()/"

#3$

/" 2 ( "+()-*

(" 1 (

#)$

/" 2 ( -/""" 1 ")

(( "+()/"#5$

/" 2 ( -/""" 1 ")

(( "+()-*("1 (

57*2 ">'4' 3"-2?.re+ex.osure immuni6ation& 2 &>'' '#1$

/ 1 " !(

#2$ / 2 " )( 0 -( 3

#3$ / 2 " )( 0 -( 7

#)$

/ 3 " )( 0? 3 - 7

#5$

/ 3 " )( 0? 7 - 28

55*Eaccine"#2 "'"1"#1$

4444 ,(-*"44444

5)*"5 1"!72#-4' 3"5!)"/

#1$

!5( ! "!+-(1 !! ."8$((""

#2$

!5( !"!+ (1 !! ."

8$((""#3$

!5( !"!+,(1 !! !D

."8,!*($((")!&:(!""

#)$

444 ,(-*"444

)0*";$5"''"&,*4'" 3"5!2-/! 1#-" '"3"5!-!'1"4' ''11" 4' ("!

22 Relative risk& (-?

3" 3"

"4' )5

1"4' 3 1#1$

#)/)3$ / #>8/61$

#2$

#)/)7$ / #>8/15>$

#3$

#)/61$ / #)3/>8$

#)$

#)/>8$ / #)3/61$

#5$

#)/102$ / #)3/10)$

)1*1/'""2"4','">'

-% ?:ntramuscular$

3!(1 "("!!'#""(#!duvant$ !"#

#2$

;9

7/24/2019 MCQ-2557-PSU

28/28

M,- 12 | 1(2$$7 | Page 25

" 1"/"0+12 ...)2*""'";)%* isolator ''1"

)3*-#- =a6ar ratio -& )$> confience interval

)*"!-""5 -- -'1!'!#1$

!9'#2$

!#3$

!9'"#)$ !9', 0. 3" - "!#

"*((-*"(( (2#5$

" &CE #

)$*"!!0*)2$ %1'"&!*)"#1$

isintegration

#2$

issoution

#3$

:ardness

#)$

&denti(ication

#5$

Dni(ormity o( dosage unit

)* - ,a..ing &1721,'#1$

"!": magnesium stearate

#2$

""!)!")"%#3$

"!":"&*)$)"%

#)$

"!": poyviny acetate )"%#5$

"!)&)!")"%

)7*",' r granulation -com.ressa4ilit inex A 33 - & angle of re.ose A$*5B""-1"-#1$

agnesium stearate

#2$ Cooida siicon dio"ide

#3$

F ,(-*"F

mcq-2557-psu

Documents